Company: BLLN
Filing Date: 2025-06-20
Form Type: DRS
Source: 0000950123-25-006095
Chunk: 189

Company: BillionToOne, Inc.
Filing Date: 2025-06-20
Form: DRS
Chunk 189
---
 then sustain profitability.” The long-term success of our business depends on securing protection of our intellectual property through patent, trade secret, trademark, and other intellectual property rights. We also utilize non-disclosureagreements and proprietary information and inventions assignment agreements with employees, consultants, contractors and other third parties and maintain physical security of our premises and physical and electronic security of our information technology systems in order to strengthen the protection of our intellectual property. As of June 5, 2025, we held 9 U.S.-issued patents, which expire between August 2038 and March 2043, and 41 foreign patents, which expire between August 2038 and September 2041. Additionally, we had 13 pending U.S. patent applications and 33 foreign patent applications. We also held 4 U.S. trademarks and 13 foreign trademarks as of December 31, 2024. Our patent strategy is focused on seeking robust coverage for our core molecular counting technology (covered by U.S. is Patent No. 11,629,381, with a pending U.S. divisional application, granted patents in Japan, Hong Kong, India, China, Australia, and Europe (validated in 17 countries), and pending applications in Brazil, Canada, Israel, South Korea, Singapore, Japan (divisional), Europe (divisional), and Hong Kong (divisional), our dilution tagging technology (cover by U.S. Patent No. 12,071,651, with a pending U.S. continuation and pending foreign applications in Canada, China, Europe, and Hong Kong), our custom-made Synthetic DNA controls (covered by U.S. Patent Nos. 11,646,100 and 12,176,066, with a pending U.S. continuation, an issued patent in Canada, and pending applications in China, Europe, and Hong Kong), and our proprietary signal processing technology (covered by U.S. Patent Nos. 11,430,543 and 12,183,437, also granted in Japan, Singapore, South Korea, Israel, Canada, Australia and Europe, and pending in Brazil, China, Hong Kong, and India), all of which is used to maximize readings taken from single blood draws. We have also recently filed several unpublished patent applications covering a range of techniques for improving the efficiency and accuracy of DNA sequencing-based assays. In addition, we file for patent protection in connection with our ongoing research and development activities, particularly those related to early-stage cancer detection. Our patents and applications generally fall into three broad